Lewis Joel

Lewis Joel is listed in filings as President and CEO at Galectin Therapeutics Inc.. This profile follows SEC Form 4 activity through Jan 22, 2026, including sale activity. Recent filings connect the profile to Galectin Therapeutics Inc. (GALT). The current snapshot covers public activity from Dec 26, 2024 to Jan 22, 2026. Reported amounts are shown as $49.6K to $88.6K. The page organizes purchases, sales, issuer links, reported share activity, and filing evidence for review as public disclosure data.